<DOC>
	<DOC>NCT02223481</DOC>
	<brief_summary>This study sought to determine whether terbogrel was an effective treatment for primary pulmonary hypertension (PPH) by comparing its efficacy and safety to that of placebo.</brief_summary>
	<brief_title>Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Primary pulmonary hypertension and New York Health Association (NYHA) chronic heart failure (CHF) functional class IIIII Ability to walk &gt;= 50 meters on the 6 minute walk test Resting mean pulmonary artery pressure &gt; 25 mmHg Mean right atrial pressure &lt;= 20 mmHg Pulmonary capillary wedge pressure &lt;= 15 mmHg Cardiac index &gt; 2.5 L/min2 SvO2 sat. &gt; 63% Male of female at least 18 years old Signed written informed consent Secondary pulmonary hypertension due to lung or systemic diseases Pregnant of nursing women, or women of childbearing potential who are not using adequate methods of birth control Concurrent systematic use of aspirin, aspirin like drugs, or nonsteroidal antiinflammatory drugs (NSAIDs) Surgery of bleeding from gastrointestinal, genitourinary tract, cerebrum or retina within past 6 weeks History of bleeding diathesis or a platelet count less than 70,000/mm3 Exercise limited by factors other than fatigue or exertional dyspnea, such as arthritis, claudication, angina, chronic obstructive pulmonary disease, or bronchial asthma Myocardial infarction, stroke, or transient ischemic attack within the preceding six months Systolic blood pressure &lt; 90 mmHg or &gt; 180 mmHg, or diastolic blood pressure &gt; 110 mmHg Known drug or alcohol dependency within one year of entry into the study Known hypersensitivity to any component of the study formulation, epoprostenol, nitric oxide, or adenosine Psychiatric or other illness or condition which, in the opinion of the principal investigator, may interfere with study participation, compliance, or other elements of the protocol Participation in an evaluation of an investigational drug within the past 30 days Portal hypertension or cirrhosis of the liver Congenital heart disease e.g., atrial septal defect; patent foramen ovale does not exclude patient from the study Appetite suppressants such as fenfluramine, dexfenfluramine, and inhibitors of serotonin uptake known to be associated with primary pulmonary hypertension, received within 3 months of entry into the study HIV positive Vasodilators. Patients will not receive Cachannel blockers during the study unless the medication was started prior to the study and the patient has been on a stable dose for at least one month prior to entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>